NO965591D0 - Combination treatment of HIV infection - Google Patents

Combination treatment of HIV infection

Info

Publication number
NO965591D0
NO965591D0 NO965591A NO965591A NO965591D0 NO 965591 D0 NO965591 D0 NO 965591D0 NO 965591 A NO965591 A NO 965591A NO 965591 A NO965591 A NO 965591A NO 965591 D0 NO965591 D0 NO 965591D0
Authority
NO
Norway
Prior art keywords
hiv infection
combination treatment
treatment
combination
hiv
Prior art date
Application number
NO965591A
Other languages
Norwegian (no)
Other versions
NO965591L (en
Inventor
Emilio A Emini
Joel R Huff
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO965591D0 publication Critical patent/NO965591D0/en
Publication of NO965591L publication Critical patent/NO965591L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
NO965591A 1994-06-27 1996-12-27 Combination treatment of HIV infection NO965591L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26708594A 1994-06-27 1994-06-27
PCT/US1995/007690 WO1996000068A2 (en) 1994-06-27 1995-06-23 Combination therapy for hiv infection

Publications (2)

Publication Number Publication Date
NO965591D0 true NO965591D0 (en) 1996-12-27
NO965591L NO965591L (en) 1996-12-27

Family

ID=23017251

Family Applications (1)

Application Number Title Priority Date Filing Date
NO965591A NO965591L (en) 1994-06-27 1996-12-27 Combination treatment of HIV infection

Country Status (14)

Country Link
EP (1) EP0767664A2 (en)
JP (1) JPH10503178A (en)
AU (1) AU2863895A (en)
CA (1) CA2193221A1 (en)
CZ (1) CZ375196A3 (en)
FI (1) FI965196A (en)
HU (1) HUT76546A (en)
IL (1) IL114208A0 (en)
MX (1) MX9700036A (en)
NO (1) NO965591L (en)
PL (1) PL317876A1 (en)
SK (1) SK163996A3 (en)
WO (1) WO1996000068A2 (en)
ZA (1) ZA955269B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689761B1 (en) * 1995-02-01 2004-02-10 Merck & Co., Inc. Combination therapy for HIV infection
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
EP0872233A1 (en) * 1997-04-14 1998-10-21 Janssen Pharmaceutica N.V. Antiretroviral compositions with improved bioavailability
GB2324242A (en) * 1997-04-18 1998-10-21 Atindra Nath Chakrabarty Medicaments for treating viral infections
EA005423B1 (en) 1999-09-24 2005-02-24 Янссен Фармацевтика Н.В. Antiviral compositions
EP3353527B1 (en) 2015-09-23 2022-12-28 Malvern Panalytical Limited Particle characterisation

Also Published As

Publication number Publication date
WO1996000068A2 (en) 1996-01-04
FI965196A0 (en) 1996-12-23
SK163996A3 (en) 1997-08-06
FI965196A (en) 1996-12-23
HUT76546A (en) 1997-09-29
PL317876A1 (en) 1997-04-28
AU2863895A (en) 1996-01-19
NO965591L (en) 1996-12-27
JPH10503178A (en) 1998-03-24
MX9700036A (en) 1997-04-30
IL114208A0 (en) 1995-10-31
HU9603567D0 (en) 1997-02-28
ZA955269B (en) 1996-02-02
CZ375196A3 (en) 1997-07-16
EP0767664A2 (en) 1997-04-16
WO1996000068A3 (en) 1996-02-22
CA2193221A1 (en) 1996-01-04

Similar Documents

Publication Publication Date Title
NO934547D0 (en) Oral treatment of Helicobacter-in-infection
NO924461D0 (en) DIPYRIDAMOL FOR THE TREATMENT OF PROLIFERACTIVE DISEASES
FI972681A (en) Anti-fungal treatment of nails
FI956339A (en) Treatment of absence of hypothalamic menstruation
FI965204A (en) Medical use of bromelain
KR950700707A (en) Dental treatment system
NO940810D0 (en) Treatment of viral infections
FI932847A0 (en) HIV proteasinhibitors are used in the treatment of AIDS
ID21874A (en) USE OF 1-HYDROXY-2-PYRIDON FOR TREATMENT OF SKIN INFECTION
NO955258D0 (en) Medical use of enzymes
NO965591D0 (en) Combination treatment of HIV infection
FI963638A (en) Procedures for the diagnosis and treatment of HIV-1 infection
EE03514B1 (en) A combination of compounds for the treatment of HIV infection or AIDS, its use and a pharmaceutical composition
FI971897A0 (en) Detection of human retroviral infection
NO942756D0 (en) Treatment of glaucoma
DE59301768D1 (en) Dental treatment unit
AU3530395A (en) Treatment of viral infections
NO963482D0 (en) Medical application of bromelain
NO20002481D0 (en) Combination therapy for the treatment of AIDS
DE69522685D1 (en) TREATMENT OF BLOOD PLASMA
DE69737088D1 (en) THERAPEUTIC AGENT FOR THE TREATMENT OF FIV INFECTIONS
NO960551D0 (en) Antibody based treatment of HIV infection
EP0655919A4 (en) Treatment of human viral infections.
AU1389897A (en) Use of chemokines for the treatment and prevention of hiv infection
GB9422923D0 (en) Treatment of viral infections